 <h1>Teflaro Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ceftaroline</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ceftaroline. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Teflaro.</p><h2>In Summary</h2><p><b>Common side effects of Teflaro include:</b> positive direct coombs test. <b>Other side effects include:</b> diarrhea.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ceftaroline: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ceftaroline (the active ingredient contained in Teflaro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking ceftaroline:</p><p>
<i>More common</i>
</p><ul>
<li>Back, leg, or stomach pains</li>
<li>bleeding gums</li>
<li>chills</li>
<li>dark urine</li>
<li>difficulty with breathing</li>
<li>fever</li>
<li>general body swelling</li>
<li>headache</li>
<li>loss of appetite</li>
<li>nausea or vomiting</li>
<li>nosebleeds</li>
<li>pale skin</li>
<li>sore throat</li>
<li>unusual tiredness or weakness</li>
<li>yellowing of the eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach tenderness</li>
<li>black, tarry stools</li>
<li>blood in the urine or stools</li>
<li>bluish color</li>
<li>changes in skin color</li>
<li>chest pain or discomfort</li>
<li>confusion</li>
<li>convulsions</li>
<li>cough</li>
<li>decreased frequency or amount of urine</li>
<li>diarrhea</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>general tiredness and weakness</li>
<li>hives or itching</li>
<li>increased blood pressure</li>
<li>increased thirst</li>
<li>light-colored stools</li>
<li>lightheadedness, dizziness, or fainting</li>
<li>lower back or side pain</li>
<li>mood changes</li>
<li>muscle pain or cramps</li>
<li>nervousness</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>painful or difficult urination</li>
<li>pinpoint red spots on the skin</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>severe abdominal or stomach cramps and pain</li>
<li>skin itching, rash, or redness</li>
<li>slow or irregular heartbeat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swelling of the face, throat, fingers, or lower legs</li>
<li>swollen glands</li>
<li>tenderness</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>upper right abdominal or stomach pain</li>
<li>watery and severe diarrhea, which may also be bloody</li>
<li>weakness or heaviness of the legs</li>
<li>weight gain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ceftaroline may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>difficulty having a bowel movement (stool)</li>
<li>flushed, dry skin fruit-like breath odor</li>
<li>increased hunger</li>
<li>increased urination</li>
<li>sweating</li>
<li>unexplained weight loss</li>
<li>welts</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ceftaroline: intravenous powder for injection</i></p><h3>General</h3><p>The most common side effects reported in adults using this drug were diarrhea, headache, nausea, pruritus, and rash.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>In clinical trials, direct antiglobulin test seroconversion was reported in 10.7% of adult patients using this drug every 12 hours (600 mg infused over 1 hour every 12 hours) and in 32.3% of those using this drug every 8 hours (600 mg infused over 2 hours every 8 hours).  Seroconversion from negative to positive direct Coombs test result was reported in 17.9% of children using this drug.</p>
<p></p>
<p>Agranulocytosis, eosinophilia, and leukopenia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Direct antiglobulin test/Coombs test seroconversion (up to 32.3%), positive direct Coombs test</p>
<p><b>Uncommon</b> (0.1% to 1%): Anemia, leukopenia, neutropenia, thrombocytopenia, prolonged prothrombin time, prolonged activated partial thromboplastin time, increased INR</p>
<p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis, eosinophilia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, nausea, constipation, vomiting, abdominal pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Clostridioides difficile colitis</p>
<p><b>Frequency not reported</b>: C difficile-associated diarrhea, dyspepsia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>In clinical trials using this drug every 12 hours or every 8 hours, rash was common; however, in a subgroup of Asian patients using this drug every 8 hours, rash was very common (18.5%).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Rash, pruritus, generalized pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria</p>
<p></p>
<p>Beta-lactam antibiotics (including cephalosporins):</p>
<p>-Postmarketing reports: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms [DRESS], acute generalized exanthematous pustulosis)<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Risk of encephalopathy was higher in patients with renal dysfunction receiving doses of this drug that were not appropriately reduced.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Headache, dizziness</p>
<p><b>Frequency not reported</b>: Convulsion</p>
<p><b>Postmarketing reports</b>: Encephalopathy<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia</p>
<p><b>Frequency not reported</b>: Decreased appetite, hyperglycemia, hyperkalemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Phlebitis, hypertension, increased blood pressure</p>
<p><b>Frequency not reported</b>: Bradycardia, palpitations<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased transaminases, increased ALT</p>
<p><b>Frequency not reported</b>: Abnormal hepatic function, hepatitis, increased AST<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pyrexia</p>
<p><b>Frequency not reported</b>: Asthenia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site reactions (erythema, phlebitis, pain)</p><h3>Hypersensitivity</h3><p>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterials.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity (e.g., urticaria, lip and face swelling), anaphylaxis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Increased blood creatinine</p>
<p><b>Frequency not reported</b>: Renal failure<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Eosinophilic pneumonia</p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals, St. Louis, MO. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Ceftaroline fosamil (Teflaro) - a new IV cephalosporin." Med Lett Drugs Ther 53 (2011): 5-6</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Teflaro (ceftaroline)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: next generation cephalosporins</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Teflaro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Pneumonia</li>
<li>Skin and Structure Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ceftaroline: intravenous powder for injection</i></p><h3>General</h3><p>The most common side effects reported in adults using this drug were diarrhea, headache, nausea, pruritus, and rash.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>In clinical trials, direct antiglobulin test seroconversion was reported in 10.7% of adult patients using this drug every 12 hours (600 mg infused over 1 hour every 12 hours) and in 32.3% of those using this drug every 8 hours (600 mg infused over 2 hours every 8 hours).  Seroconversion from negative to positive direct Coombs test result was reported in 17.9% of children using this drug.</p><p></p><p>Agranulocytosis, eosinophilia, and leukopenia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Direct antiglobulin test/Coombs test seroconversion (up to 32.3%), positive direct Coombs test</p><p><b>Uncommon</b> (0.1% to 1%): Anemia, leukopenia, neutropenia, thrombocytopenia, prolonged prothrombin time, prolonged activated partial thromboplastin time, increased INR</p><p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis, eosinophilia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, nausea, constipation, vomiting, abdominal pain</p><p><b>Uncommon</b> (0.1% to 1%): Clostridioides difficile colitis</p><p><b>Frequency not reported</b>: C difficile-associated diarrhea, dyspepsia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>In clinical trials using this drug every 12 hours or every 8 hours, rash was common; however, in a subgroup of Asian patients using this drug every 8 hours, rash was very common (18.5%).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Rash, pruritus, generalized pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p><p></p><p>Beta-lactam antibiotics (including cephalosporins):</p><p>-Postmarketing reports: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms [DRESS], acute generalized exanthematous pustulosis)<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Risk of encephalopathy was higher in patients with renal dysfunction receiving doses of this drug that were not appropriately reduced.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Headache, dizziness</p><p><b>Frequency not reported</b>: Convulsion</p><p><b>Postmarketing reports</b>: Encephalopathy<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia</p><p><b>Frequency not reported</b>: Decreased appetite, hyperglycemia, hyperkalemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Phlebitis, hypertension, increased blood pressure</p><p><b>Frequency not reported</b>: Bradycardia, palpitations<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased transaminases, increased ALT</p><p><b>Frequency not reported</b>: Abnormal hepatic function, hepatitis, increased AST<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pyrexia</p><p><b>Frequency not reported</b>: Asthenia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site reactions (erythema, phlebitis, pain)</p><h3>Hypersensitivity</h3><p>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterials.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity (e.g., urticaria, lip and face swelling), anaphylaxis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Increased blood creatinine</p><p><b>Frequency not reported</b>: Renal failure<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Eosinophilic pneumonia</p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals, St. Louis, MO. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Ceftaroline fosamil (Teflaro) - a new IV cephalosporin." Med Lett Drugs Ther 53 (2011): 5-6</p><h2>More about Teflaro (ceftaroline)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: next generation cephalosporins</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Teflaro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Pneumonia</li>
<li>Skin and Structure Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>